Healthcare Providers and Services
Company Overview of Genzyme Polyclonals S.A.S.
Genzyme Polyclonals S.A.S. operates as a subsidiary of Genzyme Corporation.
Les Carrés du Parc
10 rue des Rosiéristes - BP 54
Champagne au Mont D´Or
33 4 37 28 16 00
33 4 37 28 16 79
Key Executives for Genzyme Polyclonals S.A.S.
Chief Executive Officer and Chief Operating Officer
Compensation as of Fiscal Year 2014.
Genzyme Polyclonals S.A.S. Key Developments
Genzyme and Isis Pharmaceuticals Inc. Present Kynamro Clinical Data at the American Heart Association
Nov 18 14
Genzyme and Isis Pharmaceuticals Inc. announced that new two-year data from a phase 3 long-term extension study of KYNAMRO injection was presented at a scientific session at the annual American Heart Association meeting in Chicago, IL. In the study, a retrospective analysis showed that patients treated with KYNAMRO for a mean of two years had a significant reduction in Major Adverse Cardiovascular Events compared to two years prior to therapy. This retrospective analysis included 104 patients who enrolled in the long-term extension study of KYNAMRO after having completed one of the KYNAMRO phase 3 blinded, randomized, placebo-controlled 6-month trials in patients with homozygous and heterozygous FH. All patients who completed at least two years of treatment with KYNAMRO were included in the analysis. The rate of MACE in patients treated with KYNAMRO for two years were adjudicated by an independent committee and compared to the rate of MACE in the same patients based on their medical history prior to treatment with KYNAMRO. In this analysis, MACE were identified in 62% of patients during two years prior to KYNAMRO treatment, and 9% of patients during a mean of 24.4 months after initiation of treatment with KYNAMRO.
Genzyme Presents at Boston CEO Conference, Jun-05-2014 04:00 PM
Jun 2 14
Genzyme Presents at Boston CEO Conference, Jun-05-2014 04:00 PM. Venue: Four Seasons Hotel, 200 Boylston Street, Boston, MA 02116, Massachusetts, United States. Speakers: David Meeker.
Genzyme Receives Complete Response Letter from Food and Drug Administration on Lemtrada(TM) (alemtuzumab) Application
Dec 30 13
Genzyme announced that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its supplemental Biologics License Application seeking approval of Lemtrada (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis. A complete response letter informs companies that an application is not ready for approval. FDA has taken the position that the company has not submitted evidence from adequate and well-controlled studies that demonstrate the benefits of Lemtrada outweigh its serious adverse effects. The company understands that the conclusion is related to the design of the completed Phase 3 active comparator studies of Lemtrada in relapsing-remitting MS patients. FDA has also taken the position that one or more additional active comparator clinical trials of different design and execution are needed prior to the approval of Lemtrada.
Similar Private Companies By Industry
Recent Private Companies Transactions
Most Searched Private Companies
Sponsored Financial Commentaries